Titre:
  • Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial
Auteur:Oakman, Catherine; Di Leo, Angelo; Francis, Prudence; Crown, John; Quinaux, Emmanuel; Buyse, Marc; Azambuja, Evandro; Punzalan, L.; Piccart-Gebhart, Martine; Vila, Mireia Margeli; Andersson, Michael; Nordenskjöld, B; Jakesz, Raimund; Thürlimann, Beat; Gutiérrez, Jorge Martos J.; Harvey, Vernon; Dell'Orto, Patrizia; Viale, Giuseppe; Larsimont, Denis; Steinberg, I.; Gelber, Richard
Informations sur la publication:Annals of oncology, 24, 5, page (1203-1211), mds627
Statut de publication:Publié, 2013-05
Sujet CREF:Hématologie
Cancérologie
Mots-clés:Adjuvant
Breast cancer
Chemotherapy
Docetaxel
Doxorubicin
Sequential
MeSH keywords:Adolescent
Adult
Aged
Antineoplastic Agents -- administration & dosage -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- therapeutic use
Breast Neoplasms -- drug therapy -- mortality
Cyclophosphamide -- administration & dosage -- therapeutic use
Disease-Free Survival
Doxorubicin -- administration & dosage -- therapeutic use
Drug Administration Schedule
Female
Fluorouracil -- administration & dosage -- therapeutic use
Humans
Lymphatic Metastasis
Methotrexate -- administration & dosage -- therapeutic use
Middle Aged
Taxoids -- administration & dosage -- therapeutic use
Young Adult
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mds627
info:pii/mds627
info:scp/84877129418
info:pmid/23293111